Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Radical Minimally Invasive Surgery After Immuno-chemotherapy in Initially-unresectable Stage IIIB Non-small cell Lung Cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Standard Setting in Simulation-Based Training of Surgical Procedures: A Systematic Review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Comment on Prehabilitation in Major Abdominal Surgery

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  3. Impact of a Parastomal Bulge on Quality of Life - A Cross-sectional Study of Patients From the Danish Stoma Database

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Reasons for staying in hospital after video-assisted thoracoscopic surgery lobectomy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Functional recovery after discharge in enhanced recovery video-assisted thoracoscopic lobectomy: a pilot prospective cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Simulation-based VATS resection of the five lung lobes: a technical skills test

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Is complex segmentectomy safe?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Influence of reduced diffusing capacity and FEV1 on outcome after cardiac surgery

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Hongsheng Deng
  • Jun Liu
  • Xiuyu Cai
  • Jiawei Chen
  • Rocco Gaetano
  • René Horsleben Petersen
  • Alex Brunelli
  • Calvin S H Ng
  • Thomas A D'Amico
  • Wenhua Liang
  • Jianxing He
Vis graf over relationer

INTRODUCTION: Use of neoadjuvant immunotherapy agent in advanced stage NSCLC is controversial. Herein, we aim to report on a case series of successful conversion from initial unresectable stage cIIIB NSCLC to radical minimally invasive surgery through immunochemotherapy; with particular attention given to surgical outcomes and survival benefit of surgery.

METHODS: Fifty-one patients with initial stage cIIIB NSCLC who received PD-1 agents plus platinum-based chemotherapy between May, 2018 to August, 2020 were retrospectively identified. Surgical and oncological outcomes of enrolled patients were collected.

RESULTS: Of 31 patients who underwent subsequent resection, 23 (74.2%) patients underwent lobectomy, 1 (3.2%) underwent pneumonectomy, 5 (16.1%) underwent sleeve lobectomy, and 2 (6.5%) with bilobectomy. The median surgical time was 205 minutes (range, 100-520). The average blood loss was 185 (range: 10-1100) ml. Dense adhesions or fibrosis was noted in 15 cases. The median postoperative hospital stay was 6 (range: 3-13) days. No surgical-related mortality was recorded, only 5 patients (16.1%) experienced any postoperative morbidity (no grade 3 complications). Ten patients (32.3%) had major pathological response, with mediastinal down-staging been observed in 22/31 (71.0%) patients. With a median after up of 15.4 months, thirty-one patients that had surgery had relatively longer median DFS/PFS compared to that of either non-responders or responders that without surgery (27.5 vs. 4.7 vs. 16.7 months, respectively).

CONCLUSIONS: Radical surgery after chemoimmunotherapy in initial unresectable stage IIIB NSCLC seems to be safe with low surgical-related mortality and morbidity, and was favorably associated with longer DFS/PFS compared to those without surgery.

OriginalsprogEngelsk
TidsskriftAnnals of Surgery
Vol/bind275
Udgave nummer3
Sider (fra-til)e600-e602
ISSN0003-4932
DOI
StatusUdgivet - 1 mar. 2022

Bibliografisk note

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

ID: 68333433